Substance Over Noise — Reader Survey

This website uses cookies

Read our Privacy policy and Terms of use for more information.

Substance Over Noise — Reader Survey

Seven quick questions, about 60 seconds. I write for clinicians, patients, researchers, and industry readers, and right now every issue tries to serve all of you at once. Your answers decide what I build next and who gets sent what.

Email*

1.Which best describes you?*

Physician (MD/DO)

Advanced practice clinician (NP/PA)

Pharmacist, dietitian, nurse, or other health professional

Patient currently on or considering GLP-1 therapy

Caregiver or family member of someone on treatment

Industry, research, or media

2.What made you subscribe in the first place?

To keep up with GLP-1 and incretin trial data

To make better decisions for my patients

To make better decisions about my own treatment

For the free cheat sheets and reference tools

Someone I trust recommended it

3.Which topics do you actually read? Pick all that apply.

GLP-1 and incretin trial data

Lipids and cardiovascular risk

Obesity medicine practice, access, and policy

Muscle, body composition, and exercise

Peptides and off-label compounds

Longevity and prevention

4.How often would you like to hear from me?

Twice a week, exactly as it is now

Once a week

Only when something genuinely important lands

5.Which would you rather I build next?

Professional tools: prescribing guides, protocols, dosing references

Patient-facing material: plain-language explainers and handouts

Both, they serve different parts of my week

6.Which of these have you already downloaded or bought? Pick all that apply.

The GLP-1 Evidence Cheat Sheet (free)

The Retatrutide Cheat Sheet (free)

The Medicare GLP-1 Bridge Checklist (free)

The Obesity Trial Explorer / live trial tracker (free)

The GLP-1 Prescribing Field Guide (paid)

None of these yet

I am not sure which ones I already have

7.What is one obesity, GLP-1, metabolic-health, clinical, or patient-education problem you would pay to have solved?

Characters remaining: 400